Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$99.51 1.82 (1.86%) as of 4:30 Mon 1/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 148,000,000 as of 9/30
Market Cap: 14.73(B)
Last Volume: 1,277,109 Avg Vol: 1,232,444
52 Week Range: $56.17 - $99.45
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 138,860 239,087 321,569 948,503
Total Sell Value $12,068,485 $19,543,542 $25,590,321 $66,780,270
Total People Sold 7 8 9 13
Total Sell Transactions 18 26 46 122
End Date 2014-10-30 2014-07-29 2014-01-28 2013-01-28

   
Records found: 1296
  Page 1 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-01-09 4 AS $94.14 $188,286 D/D (2,000) 225,157 1%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 OE $12.99 $38,970 I/I 3,000 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 AS $88.73 $266,193 I/I (3,000) 43,195 11%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-24 4 AS $88.73 $177,462 D/D (2,000) 227,157 11%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 OE $12.99 $25,980 I/I 2,000 45,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 AS $95.00 $190,000 I/I (2,000) 43,195 7%     
   Lewis Alan Director   –       •      –    2014-12-04 4 OE $21.51 $161,325 D/D 7,500 28,900     -
   Lewis Alan Director   –       •      –    2014-12-04 4 S $89.90 $674,225 D/D (7,500) 21,400 -11%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 OE $38.59 $463,080 D/D 12,000 43,590     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 S $91.01 $1,092,161 D/D (12,000) 31,590 -9%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-02 4 OE $28.23 $141,150 D/D 5,000 9,593     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-02 4 S $91.82 $459,100 D/D (5,000) 4,593 -9%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-01 4 OE $14.39 $145,785 D/D 6,950 11,543     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-01 4 S $90.25 $627,238 D/D (6,950) 4,593 -10%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-11-26 4 S $88.97 $302,508 D/D (3,400) 4,593 -11%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-25 4 OE $12.99 $25,980 I/I 2,000 45,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-25 4 AS $90.00 $180,000 I/I (2,000) 43,195 9%     
   Davis George Eric SVP, General Counsel   •       –      –    2014-11-25 4 OE $26.49 $529,800 D/D 20,000 84,426     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-11-25 4 AS $89.75 $1,795,000 D/D (20,000) 64,426 9%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-12 4 S $81.51 $81,513 D/D (1,000) 228,157 -14%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 OE $12.99 $51,960 I/I 4,000 47,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 S $87.00 $348,000 I/I (4,000) 43,195 -14%     
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 OE $21.51 $430,200 D/D 20,000 96,550     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 S $86.55 $1,730,982 D/D (20,000) 76,550 -14%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-11-03 4 AS $83.54 $3,926 D/D (47) 31,590 18%     

  1296 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed